STOCK TITAN

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Kezar Life Sciences (Nasdaq: KZR) announced a 1-for-10 reverse stock split effective October 29, 2024, at 5:00 p.m. Eastern Time. The company's stock will begin trading on a post-split basis on October 30, 2024. This move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split will reduce outstanding shares from 72,962,220 to 7,296,222. Stockholders' positions will be automatically adjusted, with fractional shares rounded up to the nearest whole number. The split was approved by stockholders on June 18, 2024, with the final ratio approved by the Board on September 23, 2024.

Kezar Life Sciences (Nasdaq: KZR) ha annunciato uno split azionario inverso 1-per-10 che entrerà in vigore il 29 ottobre 2024 alle 17:00, ora orientale. Le azioni della società inizieranno a essere negoziate secondo il nuovo rapporto a partire dal 30 ottobre 2024. Questa mossa mira a ripristinare la conformità con il requisito di prezzo minimo di offerta di Nasdaq di $1.00 per azione. Lo split ridurrà il numero di azioni in circolazione da 72.962.220 a 7.296.222. Le posizioni degli azionisti verranno automaticamente adeguate, con le azioni frazionarie arrotondate al numero intero più vicino. La divisione è stata approvata dagli azionisti il 18 giugno 2024, con il rapporto finale approvato dal Consiglio il 23 settembre 2024.

Kezar Life Sciences (Nasdaq: KZR) anunció un split inverso de acciones 1 por 10 que entrará en vigor el 29 de octubre de 2024 a las 5:00 p.m., hora del este. Las acciones de la empresa comenzarán a cotizar en base al nuevo reparto el 30 de octubre de 2024. Este movimiento tiene como objetivo recuperar el cumplimiento con el requisito del precio mínimo de oferta de Nasdaq de $1.00 por acción. El split reducirá las acciones en circulación de 72.962.220 a 7.296.222. Las posiciones de los accionistas se ajustarán automáticamente, con las acciones fraccionarias redondeadas al número entero más cercano. El split fue aprobado por los accionistas el 18 de junio de 2024, con la relación final aprobada por la Junta el 23 de septiembre de 2024.

Kezar Life Sciences (Nasdaq: KZR)1대10 비율의 주식 분할을 2024년 10월 29일 동부 표준시 오후 5시에 시행한다고 발표했습니다. 회사의 주식은 2024년 10월 30일부터 새로운 비율로 거래를 시작합니다. 이 조치는 Nasdaq의 최소 매도 가격 요건인 주당 $1.00 을 충족하기 위한 것입니다. 주식 분할은 발행 주식을 72,962,220주에서 7,296,222주로 줄입니다. 주주들의 지분은 자동으로 조정되며, 분할 주식은 가장 가까운 정수로 반올림됩니다. 이 분할은 2024년 6월 18일 주주들의 승인을 받았으며, 최종 비율은 2024년 9월 23일 이사회에서 승인되었습니다.

Kezar Life Sciences (Nasdaq: KZR) a annoncé un rachat d'actions de 1 pour 10 qui entrera en vigueur le 29 octobre 2024 à 17h00, heure de l'Est. Les actions de la société commenceront à être négociées selon le nouveau ratio à partir du 30 octobre 2024. Cette mesure vise à rétablir la conformité avec l'exigence de prix minimum de Nasdaq de 1,00 $ par action. Le rachat réduira le nombre d'actions en circulation de 72 962 220 à 7 296 222. Les positions des actionnaires seront automatiquement ajustées, avec les actions fractionnaires arrondies au nombre entier le plus proche. Le rachat a été approuvé par les actionnaires le 18 juin 2024, et le ratio final a été approuvé par le Conseil d'administration le 23 septembre 2024.

Kezar Life Sciences (Nasdaq: KZR) gab bekannt, dass ein 1-zu-10 Aktienrücksplit am 29. Oktober 2024 um 17:00 Uhr Eastern Time wirksam wird. Die Aktien des Unternehmens werden ab dem 30. Oktober 2024 basierend auf dem neuen Verhältnis gehandelt. Diese Maßnahme zielt darauf ab, die Einhaltung des Mindestpreisanforderungs von Nasdaq von $1,00 pro Aktie wiederherzustellen. Der Split wird die ausstehenden Aktien von 72.962.220 auf 7.296.222 reduzieren. Die Positionen der Aktionäre werden automatisch angepasst, wobei Bruchanteile auf die nächstliegende ganze Zahl aufgerundet werden. Der Split wurde am 18. Juni 2024 von den Aktionären genehmigt, und das endgültige Verhältnis wurde am 23. September 2024 vom Vorstand genehmigt.

Positive
  • None.
Negative
  • Implementation of reverse stock split indicates inability to maintain minimum share price requirement
  • Risk of potential delisting from Nasdaq due to non-compliance with minimum bid price requirement

Insights

The 1-for-10 reverse stock split is a defensive move to maintain Nasdaq listing compliance, as KZR's stock has been trading below the $1.00 minimum bid requirement. While this mechanical change reduces outstanding shares from 72.96M to 7.29M, it doesn't alter the company's market capitalization or fundamental value. The decision to round up fractional shares to whole numbers is slightly shareholder-friendly but minimal in impact. This corporate action often signals financial distress and typically receives negative market reception, though it provides temporary price support. Historical patterns show that biotechnology companies executing reverse splits frequently experience continued price deterioration post-split, particularly when not accompanied by positive operational catalysts.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the “Effective Time”). The Company's common stock will begin trading on a post-split basis at the market open on October 30, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 18, 2024 (the “Annual Meeting”) to be effected at the Board's discretion within approved parameters. Following the Annual Meeting, the final ratio was approved by the Company's Board on September 23, 2024.

The Reverse Stock Split reduces the number of shares of the Company's outstanding common stock from 72,962,220 shares to 7,296,222 shares, subject to adjustment due to the issuance of full shares in lieu of fractional shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share.

Information for KZR Stockholders

As a result of the reverse stock split, every ten pre-split shares of common stock outstanding will become one share of common stock. The Company's transfer agent, Computershare Trust Company, N.A., will serve as the exchange agent for the reverse stock split.

Stockholders of record holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in "street name" will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and will not be required to take any action in connection with the reverse stock split.

No fractional shares will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will be entitled to the rounding up of the fractional share to the nearest whole number.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

Investor and Media Contact:

Gitanjali Jain

Senior Vice President, Investor Relations and External Affairs

Kezar Life Sciences, Inc.

gjain@kezarbio.com

Source: Kezar Life Sciences

FAQ

When will Kezar Life Sciences (KZR) reverse stock split take effect?

The 1-for-10 reverse stock split will take effect on October 29, 2024, at 5:00 p.m. Eastern Time, with post-split trading beginning on October 30, 2024.

How many shares will KZR have after the reverse stock split?

After the 1-for-10 reverse stock split, KZR's outstanding shares will reduce from 72,962,220 to 7,296,222 shares.

Why is Kezar Life Sciences (KZR) conducting a reverse stock split?

KZR is conducting the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share to maintain its listing on The Nasdaq Capital Market.

Do KZR shareholders need to take any action for the reverse stock split?

No, stockholders holding shares electronically or in street name don't need to take any action. Positions will be automatically adjusted to reflect the reverse stock split.

Kezar Life Sciences, Inc.

NASDAQ:KZR

KZR Rankings

KZR Latest News

KZR Stock Data

53.99M
7.30M
14.8%
63.94%
1.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO